Investigation of correlation between antitumor effect of combined lapatinib/capecitabine therapy and p95HER2, PTEN and PIK3CA in patients with HER2 positive breast cancer
Phase of Trial: Phase IV
Latest Information Update: 21 May 2018
At a glance
- Drugs Lapatinib (Primary) ; Capecitabine
- Indications Breast cancer
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- 14 May 2018 Status changed from active, no longer recruiting to completed.
- 07 Jun 2016 Interim results (n=80) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 28 Jul 2015 Status changed from recruiting to active, no longer recruiting as per University Hospital Medical Information Network - Japan.